Suchergebnisse - "Pavan, Alberto"

PubPharm (27)

1

Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer : Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World

enthalten in: The oncologist | 2024

von Pasello, G. | Lorenzi, M. | Scattolin, D. | +16

2

Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer : a multicentric analysis

enthalten in: Frontiers in immunology | 2024

von Bonanno, L. | Calvetti, L. | Dal Maso, A. | +10

3

Structural adaptability and surface activity of tardigrade-inspired peptides

enthalten in: bioRxiv.org | 2023

von Giubertoni, G. | Chagri, S. | Argudo, P. | +10

4

Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors

enthalten in: British journal of cancer | 2022

von Zulato, E. | Del Bianco, P. | Nardo, G. | +11

5

Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer

enthalten in: Translational lung cancer research | 2022

von Wang, Y. | Peng, L. | Zhao, M. | +27

6

Liquid biopsy and non-small cell lung cancer : are we looking at the tip of the iceberg?

enthalten in: British journal of cancer | 2022

von Bonanno, L. | Dal Maso, A. | Pavan, A. | +6

7

Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab

enthalten in: The oncologist | 2022

von Pasello, G. | Lorenzi, M. | Calvetti, L. | +19

ErratumIn: Oncologist. 2022 Aug 06;:. - PMID 35932280

8

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network : The ROVID study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Dieci, M. | Azzarello, G. | Zagonel, V. | +23

9

Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer : Pretreatment Predictors and Correlation With Outcome

enthalten in: The oncologist | 2022

von Pavan, A. | Ferro, A. | Fortarezza, F. | +11

10

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer : Outcome and Safety in the Real World: FLOWER Study

enthalten in: The oncologist | 2022

von Lorenzi, M. | Ferro, A. | Cecere, F. | +19

CommentIn: Oncologist. 2022 Mar 4;27(2):79-81. - PMID 35641221